Glenmark In Talks With Three Firms To Re-license Diabetes Drug

NEW DELHI - India's Glenmark Pharmaceuticals is again in discussions with at least three companies to license out its experimental DPP-4 inhibitor drug melogliptin (GRC 8200), according to a company official